FindTrial
Sign In

High Dose Chemotherapy

DRUG2 trials

Sponsors

Eastern Cooperative Oncology Group, National Cancer Institute (NCI)

Conditions

Anaplastic Large Cell Lymphoma, ALK-NegativeFollicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypePeripheral T-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma

Phase 2

Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma
Not yet recruitingNCT07572123
National Cancer Institute (NCI)Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Start: 2026-12-04End: 2029-03-31Target: 374Updated: 2026-05-13

Phase 3

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingNCT06724237
Eastern Cooperative Oncology GroupAnaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type +1
Start: 2025-01-30End: 2033-12-01Target: 294Updated: 2026-05-15